SEC EDGAR · company profile · free

AMGEN INC due diligence

Who AMGEN INC (AMGN) is on the public record: identity, annual results, what it filed in the last year and why, straight from SEC EDGAR.

1007 filings in EDGAR's recent index, 672 of them Form 4 insider filings · view the filings on SEC EDGAR · source: SEC EDGAR submissions index and XBRL financial data

At a glance

AMGEN INC (AMGN) is a large accelerated filer incorporated in Delaware, classified under SIC 2836 (Biological Products, (No Diagnostic Substances)), and lists on Nasdaq. Its fiscal year ends December 31.

For the fiscal year ended December 31, 2025, its 10-K reported revenue of $36.8B, up 10.0% from the year before, net income of $7.7B, and total assets of $90.6B.

In the twelve months to October 9, 2026 it made 127 filings on EDGAR, including 1 annual report, 3 quarterly reports, 10 current reports on Form 8-K, and 86 Form 4 insider filings, plus 3 prospectus supplements and free writing prospectuses for its securities offerings. Its 8-Ks were filed most often for results of operations (4), officer or director changes (2), and a material agreement (1).

CIK
0000318154
Filer status
Large accelerated filer
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
Incorporated
Delaware
Listed on
Nasdaq
Tickers
AMGN
Fiscal year end
12-31

Annual results

Fiscal year endedRevenueNet incomeTotal assets
2025-12-31$36.8B +10.0%$7.7B +88.5%$90.6B
2024-12-31$33.4B +18.6%$4.1B -39.1%$91.8B
2023-12-31$28.2B$6.7B$97.2B
As reported in each 10-K's XBRL data on SEC EDGAR (revenue tag RevenueFromContractWithCustomerExcludingAssessedTax); a later 10-K's restatement replaces the earlier figure.
FilingFiledPeriodAccession
Annual report (10-K)2026-02-132025-12-310000318154-26-000010
Quarterly report (10-Q)2026-08-052026-06-300000318154-26-000126
Current report (8-K)2026-08-042026-08-040000318154-26-000124

Filing activity

127 filings since 2025-10-09, 3 of them prospectus supplements and free writing prospectuses (not listed below). By form:

4
86
144
10
8-K
10
10-Q
3
DEFA14A
3
11-K
2
SCHEDULE 13G
2
10-K
1

8-K items in the last 12 months: results of operations (Item 2.02, 4) · officer or director changes (Item 5.02, 2) · a material agreement (Item 1.01, 1) · ending a material agreement (Item 1.02, 1) · a cybersecurity incident (Item 1.05, 1) · shareholder vote results (Item 5.07, 1).

FiledFormDocumentPeriod
2026-09-043PRIMARY DOCUMENT2026-09-01
2026-08-134PRIMARY DOCUMENT2026-08-11
2026-08-13144Form 144 notice of proposed sale
2026-08-124PRIMARY DOCUMENT2026-08-07
2026-08-11144Form 144 notice of proposed sale
2026-08-104PRIMARY DOCUMENT2026-08-07
2026-08-104PRIMARY DOCUMENT2026-08-07
2026-08-104PRIMARY DOCUMENT2026-08-07
2026-08-074PRIMARY DOCUMENT2026-08-06
2026-08-074PRIMARY DOCUMENT2026-08-06
free alert

Free. One email a day at most, only when something changes. Confirm by email first; unsubscribe with one click. Privacy.

The full due-diligence dossier on AMGEN INC

The free view above is identity and filing dates. The paid dossier reads the filings: business and segments, financial trend, insider and institutional activity, litigation and risk-factor themes, recent news, and the red flags, every claim cited and delivered with a data appendix.

agents: POST /v1/dossier with {"ticker":"AMGN"} over x402 or MPP, $0.85

Sample output and API docs · all reports

AMGN insider filingsAll company profiles13F fund holdingsAll reports

Generated from public SEC EDGAR filings. Filing data is shown as filed. This is information, not investment advice.